Edgewise Therapeutics
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Edgewise Therapeutics sits in the top decile of US sponsors by registered trial count (#934 of 15,742 sponsors by registered trial count).
Edgewise Therapeutics: 15 sponsored US clinical trials, 2 recruiting.
Edgewise Therapeutics sponsors 15 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 8 completed. 0 of these trials are in Phase 3-4 (later-stage) and 15 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Duchenne Muscular Dystrophy, with 2 trials.
Top-decile sponsor footprint
Edgewise Therapeutics ranks in the top decile of sponsors by registered trial count (#934 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Open and recent trials
15 total, page 1 of 1
A Study to Evaluate EDG-7500 in Adults With Hepatic Impairment
NCT07324616
A Study of EDG-15400 in Healthy Adults
NCT07177066
A Study of EDG-7500 in Adults With Hypertrophic Cardiomyopathy (CIRRUS-HCM)
NCT06347159
Phase 2 Study of EDG-5506 in Children and Adolescents With Duchenne Muscular Dystrophy Previously Treated With Gene Therapy
NCT06100887
Phase 2 Study of EDG-5506 in Becker Muscular Dystrophy (GRAND CANYON)
NCT05291091
A Study of EDG-5506 in Children With Duchenne Muscular Dystrophy (LYNX)
NCT05540860
A Study to Evaluate EDG-7500 in Caucasian and Japanese Adults
NCT07456059
A Study to Evaluate EDG-7500 in People With Renal Impairment
NCT07034768
A Study to Evaluate Effect of Verapamil and Food of Sevasemten in Healthy Volunteers
NCT06916897
A Study to Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C]-EDG-7500
NCT06738836
A Study of EDG-7500 in Healthy Adults
NCT06011317
Absorption, Metabolism, Excretion and Absolute Bioavailability of EDG-5506 in Healthy Volunteers
NCT05730842
A Study to Assess the Feasibility of Non-invasive Dried Blood Sampling
NCT05492734
A Study of EDG-5506 in Adult Males With Becker Muscular Dystrophy
NCT05160415
A Study to Assess Safety, Tolerability, and PK of EDG-5506 in Healthy Volunteers and Becker Muscular Dystrophy Adults
NCT04585464
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 11 |
| Phase 2 | 4 |
Therapeutic Areas
What is open in the Edgewise Therapeutics pipeline
2 recruiting of 15 indexed (13% open); 8 completed (53%).
Phase mix: 0 late (III/IV) vs 15 early (I/II) (early-phase heavy).
Top condition: Duchenne Muscular Dystrophy (2 trials), 4 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Edgewise Therapeutics: open-pipeline peers nationwide
Peers matched on 15 registered trials and 13% open enrollment, not the therapeutic-area sidebar.
Edgewise Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 15 trials (± recruiting share)
- Allakos · 15 trials · 0% recruiting
- Arbor Research Collaborative for Health · 15 trials · 33% recruiting
- Arena Pharmaceuticals · 15 trials · 0% recruiting
- Arrowhead Pharmaceuticals · 15 trials · 20% recruiting
Sponsors near 13% open enrollment (± trial volume)
- Chiesi Farmaceutici S.p.A. · 13% recruiting · 30 trials
- Dizal Pharmaceuticals · 13% recruiting · 15 trials
- EpicentRx · 13% recruiting · 15 trials
- European Organisation for Research and Treatment of Cancer - EORTC · 13% recruiting · 15 trials
Related
What to do with this Edgewise Therapeutics page
15 registered trials is a research-attention snapshot, not an endorsement of Edgewise Therapeutics or any single study.
- 2 of Edgewise Therapeutics's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Duchenne Muscular Dystrophy is the condition Edgewise Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Duchenne Muscular Dystrophy trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Edgewise Therapeutics pipeline card: 15 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.